| Excerpt | Relevance | Reference |
|---|
| "Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoaxazolepropionate acid receptor antagonist that has recently been approved for treating focal epilepsy as a secondary drug of choice." | 5.56 | Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy. ( Chonan, M; Kanamori, M; Nakasato, N; Osawa, SI; Saito, R; Suzuki, H; Tominaga, T; Watanabe, M, 2020) |
| "Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoaxazolepropionate acid receptor antagonist that has recently been approved for treating focal epilepsy as a secondary drug of choice." | 1.56 | Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy. ( Chonan, M; Kanamori, M; Nakasato, N; Osawa, SI; Saito, R; Suzuki, H; Tominaga, T; Watanabe, M, 2020) |